CAR-T cell treatment for advanced blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a type of immunotherapy called CAR-T cells, which are specially engineered white blood cells designed to find and destroy cancer cells. It is for people with blood cancers that have come back or not responded to other treatments and who have few remaining options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer that is life-threatening or seriously affects your quality of life.
- Your cancer has come back or did not respond to standard treatments, and no other options are working for you.
- You are willing to try an experimental treatment called CAR-T cells, which are made from your own immune cells.
- Your body has enough healthy blood cells (especially lymphocytes) to safely undergo this treatment.
- Your heart, lungs, liver, kidneys, and blood clotting are working well enough for the procedure.
- You do not have HIV, hepatitis B or C, or an active serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to attack cancer cells that have certain markers (CD19 or BCMA). It is for people with blood cancers like multiple myeloma or certain lymphomas that have not responded to multiple prior treatments. The goal is to see if this treatment can help when other options have failed.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This study tests a new type of immunotherapy that uses your own immune cells, modified in a lab, to find and attack cancer cells in blood cancers like leukemia, lymphoma, and multiple myeloma. It is for people whose cancer has come back or not responded to standard treatments.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Hear when a new Relapsed and Refractory Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.